Parabilis Medicines (PBLS) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $22.75, -9.65% vs the prior close of $25.18.
- Volume 1.12M shares, 1.4x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
PBLS slides 9.7% to $22.75, a 3-month low, 4 down days in a row. Closed at $22.75, -9.65% vs the prior close of $25.18. Day range $22.66–$25.70, opened at $25.39.
PBLS daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — PBLS slides 9.7% to $22.75, a 3-month low, 4 down days in a row
- Closed at $22.75, -9.65% vs the prior close of $25.18. Day range $22.66–$25.70, opened at $25.39.
- Volume was 1.12M shares, 1.4x its 50-day average of 818.32K.
- Price is -35.2% vs its 50-day average ($35.09).
- 52-week range $22.66–$42.49; today's close sits at 0% of that range, 46.5% below the 52-week high.
- That makes 4 straight losses.
Oct 15, 2026 — PBLS dips 2.7% to $25.18, a 3-month low, 3 down days in a row
- Closed at $25.18, -2.74% vs the prior close of $25.89. Day range $24.80–$26.44, opened at $25.76.
- Volume was 955.20K shares, 1.2x its 50-day average of 804.60K.
- Price is -28.8% vs its 50-day average ($35.34).
- 52-week range $24.51–$42.49; today's close sits at 4% of that range, 40.7% below the 52-week high.
- That makes 3 straight losses.
Oct 14, 2026 — PBLS slides 3.6% to $25.89, a 3-month low
- Closed at $25.89, -3.58% vs the prior close of $26.85. Day range $25.73–$27.39, opened at $27.00.
- Volume was 764.90K shares, 1.0x its 50-day average of 796.44K.
- Price is -27.1% vs its 50-day average ($35.54).
- 52-week range $24.51–$42.49; today's close sits at 8% of that range, 39.1% below the 52-week high.
Oct 13, 2026 — PBLS slides 7.3% to $26.85, a 3-month low
- Closed at $26.85, -7.25% vs the prior close of $28.95. Day range $26.72–$29.50, opened at $29.45.
- Volume was 1.19M shares, 1.5x its 50-day average of 786.61K.
- Price is -24.9% vs its 50-day average ($35.74).
- 52-week range $24.51–$42.49; today's close sits at 13% of that range, 36.8% below the 52-week high.
Oct 12, 2026 — PBLS jumps 5.3% to $28.95
- Closed at $28.95, +5.35% vs the prior close of $27.48. Day range $26.83–$29.50, opened at $27.38.
- Volume was 1.20M shares, 1.6x its 50-day average of 769.67K.
- Price is -19.3% vs its 50-day average ($35.88).
- 52-week range $24.51–$42.49; today's close sits at 25% of that range, 31.9% below the 52-week high.
Oct 9, 2026 — PBLS dips 2.2% to $27.48, a 1-month low, 7 down days in a row
- Closed at $27.48, -2.17% vs the prior close of $28.09. Day range $27.21–$29.50, opened at $28.15.
- Volume was 1.09M shares, 1.4x its 50-day average of 755.83K.
- Price is -23.6% vs its 50-day average ($35.98).
- 52-week range $24.51–$42.49; today's close sits at 17% of that range, 35.3% below the 52-week high.
- That makes 7 straight losses.
Oct 8, 2026 — PBLS dips 2.5% to $28.09, a 1-month low on 1.9x normal volume
- Closed at $28.09, -2.53% vs the prior close of $28.82. Day range $26.14–$28.90, opened at $28.42.
- Volume was 1.39M shares, 1.9x its 50-day average of 735.20K — unusually heavy trading.
- Price is -22.1% vs its 50-day average ($36.08).
- 52-week range $24.51–$42.49; today's close sits at 20% of that range, 33.9% below the 52-week high.
- That makes 6 straight losses.
Oct 7, 2026 — PBLS ends flat (-0.1%) to $28.82, a 1-month low, 5 down days in a row
- Closed at $28.82, -0.14% vs the prior close of $28.86. Day range $27.56–$30.36, opened at $28.78.
- Volume was 994.00K shares, 1.4x its 50-day average of 722.54K.
- Price is -20.3% vs its 50-day average ($36.15).
- 52-week range $24.51–$42.49; today's close sits at 24% of that range, 32.2% below the 52-week high.
- That makes 5 straight losses.
Oct 6, 2026 — PBLS dips 2.3% to $28.86, a 1-month low, 4 down days in a row
- Closed at $28.86, -2.27% vs the prior close of $29.53. Day range $28.17–$29.73, opened at $29.44.
- Volume was 979.20K shares, 1.4x its 50-day average of 707.40K.
- Price is -20.3% vs its 50-day average ($36.21).
- 52-week range $24.51–$42.49; today's close sits at 24% of that range, 32.1% below the 52-week high.
- That makes 4 straight losses.
Oct 5, 2026 — PBLS dips 2.5% to $29.53, a 1-month low, 3 down days in a row
- Closed at $29.53, -2.48% vs the prior close of $30.28. Day range $28.56–$30.82, opened at $30.41.
- Volume was 572.50K shares, 0.8x its 50-day average of 702.94K.
- Price is -18.6% vs its 50-day average ($36.27).
- 52-week range $24.51–$42.49; today's close sits at 28% of that range, 30.5% below the 52-week high.
- That makes 3 straight losses.
Oct 2, 2026 — PBLS dips 0.5% to $30.28, a 1-month low
- Closed at $30.28, -0.53% vs the prior close of $30.44. Day range $28.30–$30.63, opened at $30.34.
- Volume was 881.20K shares, 1.3x its 50-day average of 695.68K.
- Price is -16.6% vs its 50-day average ($36.31).
- 52-week range $24.51–$42.49; today's close sits at 32% of that range, 28.7% below the 52-week high.
PBLS latest news & SEC filings
Every SEC filing by or about PBLS in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Sep 15, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Sep 2, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
Aug 25, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 25, 2026 · Form 3 — New insider holdings
Initial insider ownership statement (Form 3) — a new director, officer or 10% owner disclosed their holdings
Aug 25, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Aug 14, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 13, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $148.00K (prior year $0)
- Net income: -$52.46M (prior year -$34.81M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$2.32 (prior year -$22.28) (loss narrowed vs Jun 30, 2025)
Aug 13, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Aug 6, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 22, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Ra Capital Management, L.P. bought 47,250 shares at $29.77 (≈$1.41M) on Jul 22, 2026
- Ra Capital Management, L.P. bought 47,250 shares at $29.77 (≈$1.41M) on Jul 22, 2026
- Ra Capital Nexus Fund Iii, L.P. bought 47,250 shares at $29.77 (≈$1.41M) on Jul 22, 2026
- Ra Capital Nexus Fund Iii, L.P. bought 47,250 shares at $29.77 (≈$1.41M) on Jul 22, 2026
- Shah Rajeev M. bought 47,250 shares at $29.77 (≈$1.41M) on Jul 22, 2026
- Shah Rajeev M. bought 47,250 shares at $29.77 (≈$1.41M) on Jul 22, 2026
- …plus 19 more transaction lines in the filing.
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Jun 29, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jun 29, 2026 · Form 3 — New insider holdings
Initial insider ownership statement (Form 3) — a new director, officer or 10% owner disclosed their holdings
Things to know before you trade PBLS
- Last results release: Aug 13, 2026 (8-K Item 2.02).
- How much it moves: over the last 20 sessions the average daily move was 4.30% (largest 12.7%). That is a volatile stock.
- Liquidity: about 989.92K shares (≈$22.52M) trade per day on average.
- 52-week position: $22.75 vs a range of $22.66–$42.49 (0% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 25 open-market buys, 0 sales; latest: Capital Management, L.P. Ra bought 47,250 shares on Jul 22, 2026.
- Latest filings: 8-K Sep 15, 2026; 8-K Sep 2, 2026; 8-K Aug 25, 2026.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
PBLS market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 25.39 | 25.70 | 22.66 | 22.75 | 1.12M |
| Oct 15, 2026 | 25.76 | 26.44 | 24.80 | 25.18 | 955.20K |
| Oct 14, 2026 | 27.00 | 27.39 | 25.73 | 25.89 | 764.90K |
| Oct 13, 2026 | 29.45 | 29.50 | 26.72 | 26.85 | 1.19M |
| Oct 12, 2026 | 27.38 | 29.50 | 26.83 | 28.95 | 1.20M |
| Oct 9, 2026 | 28.15 | 29.50 | 27.21 | 27.48 | 1.09M |
| Oct 8, 2026 | 28.42 | 28.90 | 26.14 | 28.09 | 1.39M |
| Oct 7, 2026 | 28.78 | 30.36 | 27.56 | 28.82 | 994.00K |
| Oct 6, 2026 | 29.44 | 29.73 | 28.17 | 28.86 | 979.20K |
| Oct 5, 2026 | 30.41 | 30.82 | 28.56 | 29.53 | 572.50K |
| Oct 2, 2026 | 30.34 | 30.63 | 28.30 | 30.28 | 881.20K |
| Oct 1, 2026 | 31.99 | 32.63 | 29.71 | 30.44 | 885.80K |
| Sep 30, 2026 | 31.95 | 32.86 | 31.20 | 32.29 | 547.10K |
| Sep 29, 2026 | 32.84 | 33.74 | 31.20 | 31.91 | 453.90K |
| Sep 28, 2026 | 31.02 | 33.76 | 30.17 | 32.57 | 809.60K |
| Sep 25, 2026 | 32.32 | 32.32 | 29.57 | 31.20 | 1.12M |
| Sep 24, 2026 | 33.32 | 33.73 | 31.06 | 32.47 | 1.17M |
| Sep 23, 2026 | 37.89 | 37.89 | 32.95 | 33.31 | 1.11M |
| Sep 22, 2026 | 37.41 | 38.73 | 35.51 | 38.17 | 865.50K |
| Sep 21, 2026 | 41.58 | 42.32 | 34.72 | 36.93 | 1.71M |
About Parabilis Medicines
Parabilis Medicines (PBLS) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in CAMBRIDGE, MA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1657677.
PBLS board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Alexis Borisy | Director | Jun 15, 2026 |
| Edward M Fitzgerald | Director | Jun 15, 2026 |
| Richard Klausner | Director | Jun 11, 2026 |
| Peter Kolchinsky | Director | Jul 22, 2026 |
| Mathai Mammen | President & CEO | Jun 9, 2026 |
| Capital Management, L.P. Ra | Director | Jul 22, 2026 |
| Capital Healthcare Fund Lp Ra | Director | Jul 22, 2026 |
| Capital Nexus Fund Iii, L.P. Ra | Director | Jul 22, 2026 |
| Alan Sebulsky | Director | Jun 16, 2026 |
| Rajeev M. Shah | Director | Jul 22, 2026 |
| Jake Simson | Director | Jun 11, 2026 |
| Craig Tendler | Director | Aug 25, 2026 |
| Barbara Weber | Director | Jun 11, 2026 |
| Krishna Yeshwant | Director | Jun 11, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Mohammed Fawzi Benzaghou | Chief Medical Officer | Jun 9, 2026 |
| Helen Huei-In Ho | See Remarks | Jun 9, 2026 |
| Teresa Jurgensen | General Counsel | Jun 9, 2026 |
| Thomas Rodolpho Kotarakos | Chief Financial Officer | Jun 9, 2026 |
| Mathai Mammen | President & CEO | Jun 9, 2026 |
| Rohin Mhatre | See Remarks | Jun 9, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jul 22, 2026 | Capital Management, L.P. Ra | Buy | 47,250 | $29.77 |
| Jul 22, 2026 | Capital Management, L.P. Ra | Buy | 47,250 | $29.77 |
| Jul 22, 2026 | Capital Nexus Fund Iii, L.P. Ra | Buy | 47,250 | $29.77 |
| Jul 22, 2026 | Capital Nexus Fund Iii, L.P. Ra | Buy | 47,250 | $29.77 |
| Jul 22, 2026 | Rajeev M. Shah | Buy | 47,250 | $29.77 |
| Jul 22, 2026 | Rajeev M. Shah | Buy | 47,250 | $29.77 |
| Jul 22, 2026 | Capital Healthcare Fund Lp Ra | Buy | 47,250 | $29.77 |
| Jul 22, 2026 | Capital Healthcare Fund Lp Ra | Buy | 47,250 | $29.77 |
| Jul 22, 2026 | Peter Kolchinsky | Buy | 47,250 | $29.77 |
| Jul 22, 2026 | Peter Kolchinsky | Buy | 47,250 | $29.77 |
| Jul 22, 2026 | Capital Management, L.P. Ra | Buy | 47,250 | $29.77 |
| Jul 22, 2026 | Capital Management, L.P. Ra | Buy | 47,250 | $29.77 |
| Jul 22, 2026 | Capital Nexus Fund Iii, L.P. Ra | Buy | 47,250 | $29.77 |
| Jul 22, 2026 | Capital Nexus Fund Iii, L.P. Ra | Buy | 47,250 | $29.77 |
| Jul 22, 2026 | Rajeev M. Shah | Buy | 47,250 | $29.77 |
PBLS financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| No annual XBRL figures available (foreign filers often report on Form 20-F). | ||||
Latest balance sheet: total assets $1.18B, total liabilities $127.53M, cash $1.09B (as of Jun 30, 2026).
PBLS earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 13, 2026 | 8-K Item 2.02 (results) | $35.67 |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on PBLS
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.